Sequential gemcitabine–docetaxel in BCG-naïve and BCG-failure non–muscle-invasive bladder cancer: a systematic review and meta-analysis - Takeaways - MDSpire

Sequential gemcitabine–docetaxel in BCG-naïve and BCG-failure non–muscle-invasive bladder cancer: a systematic review and meta-analysis

  • By

  • Bandar Alhubaishy

  • Ibrahim Beshawri

  • Inam Abulreish

  • Omar Alnajar

  • Hamad Radhi

  • Abduljawad Saleh

  • Saher Alwafi

  • Abdulghafour Halawani

  • July 9, 2026

  • 0 min

Share

  • 1

    Intravesical gemcitabine and docetaxel (GEM/DOCE) is evaluated for efficacy and safety in treating high-risk non-muscle-invasive bladder cancer (NMIBC).

  • 2

    The systematic review included nine studies with 883 patients, showing a 12-month pooled recurrence-free survival of 73.75%.

  • 3

    BCG-naïve patients had significantly better 12-month recurrence-free survival rates compared to BCG-failure patients (82.50% vs. 60.00%).

  • 4

    GEM/DOCE demonstrated high progression-free survival (95.57%) and overall survival (97.32%) at 12 months, with manageable adverse events.

  • 5

    The study highlights the need for further prospective research to optimize treatment protocols for GEM/DOCE in NMIBC.

Original Source(s)

Sequential gemcitabine–docetaxel in BCG-naïve and BCG-failure non–muscle-invasive bladder cancer: a systematic review and meta-analysis

  • by Bandar Alhubaishy, Ibrahim Beshawri, Inam Abulreish, Omar Alnajar, Hamad Radhi, Abduljawad Saleh, Saher Alwafi, Abdulghafour Halawani

  • July 9, 2026

Related Content

Ectopic craniopharyngioma recurrence: a case report and literature review

Identification and validation of prognostic genes associated with clear cell renal cell carcinoma: based on public whole transcriptome sequencing datasets

Regression of retinal capillary hemangioblastoma with systemic belzutifan in von Hippel–Lindau disease: a case report